ArticleFrontiers in pharmacology2025
Prognostic significance and multivariate modeling of COL4A family genes and HMGA2 in glioma.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The expression pattern and prognostic relevance of p120-catenin, COL4A2 and SOX10 in glioma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COL4As, a group of six homologous genes that encode the type IV collagen α chains (α1-α6), have been identified as the main components of the collagen network in brain basement membranes. The distribution and generation changes of type IV collagen have been reported during glioma progression, but its underlying function of COL4As in glioma was still unclear. Methods: Based on the data of TCGA glioma cohort, we analyzed the correlation of COL4A family genes with the clinical characteristics and prognosis of glioma patients. By performing correlation and functional enrichment analysis, the interaction network of COL4As and their related genes in glioma were constructed to demonstrate the functional differences between COL4A members. By further screening the COL4As downstream factors, we sorted out the COL4As coregulated gene that could be the independent prognostic factor for glioma. Results: We found the high expressions in COL4A1 and COL4A2 were positively related to a worse prognosis of glioma patient, while, in COL4A3 and COL4A4 were predicted to a better prognosis. However, none of COL4As could function as an independent prognostic factor for glioma. HMGA2 is a coregulatory target of COL4A members through the COL4As-H19/HOTRAI-miR148a/miR222-HMGA2 axis. By being involved in the infiltration of Th2 cells and macrophages, HMGA2 could serve as an independent prognostic biomarker for glioma. Conclusion: In summary, our study revealed a potential common target of COL4A members HMGA2, which could serve as a novel prognostic factor for the diagnosis and therapy of glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.